Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chemically induced degradation of epigenetic targets
Md Kabir, Xufen Yu, H. Ümit Kanıskan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 13, pp. 4313-4342
Open Access | Times Cited: 12

Showing 12 citing articles:

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2
Julia Velez, Brandon Dale, Kwang‐Su Park, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116154-116154
Closed Access | Times Cited: 12
Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer
Xufen Yu, Dongxu Li, Jithesh Kottur, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 16168-16186
Closed Access | Times Cited: 19
Epigenetic Therapy in Hormone Positive Breast Cancer: The Role of PIK3CA
Ryan Blawski, Eneda Toska
Current Breast Cancer Reports (2025) Vol. 17, Iss. 1
Closed Access
Design, Synthesis, and Biological Evaluation of Novel BTK-targeting Proteolysis Targeting Chimeras (PROTACs) with Enhanced Pharmacokinetic Properties
Ying‐Hung Lin, Jing Liu, Xiaohe Tian, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117420-117420
Closed Access
Self‐Oxygenating PROTAC Microneedle for Spatiotemporally‐Confined Protein Degradation and Enhanced Glioblastoma Therapy
Xingyu Jiang, Yi Lai, Wenzheng Xia, et al.
Advanced Materials (2025)
Open Access
Targeted degradation of CDK4/6 by LA-CB1 inhibits EMT and suppresses tumor growth in orthotopic breast cancer
Jingliang He, Shunfang Liu, Siyi Zhang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Discovery of the First-in-class DOT1L PROTAC Degrader
Hyerin Yim, Renhong Sun, Zhongli Xu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117595-117595
Closed Access
Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation
Zhijie Deng, Jerrel L. Catlett, Youngeun Lee, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader
Md Kabir, Lihuai Qin, Kaixiu Luo, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6880-6892
Closed Access | Times Cited: 3
Liver-targeting chimeras as a potential modality for the treatment of liver diseases
Chuanjie Chen, Yongzhang Pan, Xiaoyu Yang, et al.
Journal of Controlled Release (2024) Vol. 374, pp. 627-638
Closed Access | Times Cited: 3
PRMT7 in cancer: Structure, effects, and therapeutic potentials
Guan‐Jun Yang, Yanjun Liu, Ru-Yi Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117103-117103
Closed Access | Times Cited: 2
Modular Assembly of Heterotrifunctional Molecules Enabled by Iodosulfonylation of Allenes and Subsequent Amination
Xiaofeng Lin, Peng Cao, Shijie Liu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
A review of the known MTA-cooperative PRMT5 inhibitors
Mei Hu, Xiang Chen
RSC Advances (2024) Vol. 14, Iss. 53, pp. 39653-39691
Open Access
Page 1

Scroll to top